Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 49.45 | 52.51 | 52.62 | 32.45 | 44.05 | 42.05 | 40.93 | 53.81 | 51.00 | 42.59 | 48.75 | 48.43 |
| Expenses | 46.74 | 49.71 | 49.67 | 36.11 | 40.62 | 38.03 | 37.49 | 49.37 | 45.87 | 39.05 | 42.05 | 44.10 |
| Operating Profit | 2.71 | 2.80 | 2.95 | -3.66 | 3.43 | 4.02 | 3.44 | 4.44 | 5.13 | 3.54 | 6.70 | 4.33 |
| OPM % | 5.48% | 5.33% | 5.61% | -11.28% | 7.79% | 9.56% | 8.40% | 8.25% | 10.06% | 8.31% | 13.74% | 8.94% |
| Other Income | 0.24 | 0.13 | 0.30 | 0.33 | 0.14 | 0.00 | 0.22 | 0.55 | 0.29 | 0.25 | 0.16 | 0.42 |
| Interest | 1.49 | 1.45 | 1.24 | 1.29 | 1.35 | 1.40 | 1.15 | 1.31 | 1.23 | 1.23 | 2.76 | 1.63 |
| Depreciation | 1.32 | 1.33 | 1.85 | 1.47 | 1.47 | 1.47 | 1.56 | 1.52 | 1.52 | 1.52 | 1.93 | 1.59 |
| Profit before tax | 0.14 | 0.15 | 0.16 | -6.09 | 0.75 | 1.15 | 0.95 | 2.16 | 2.67 | 1.04 | 2.17 | 1.53 |
| Tax % | 78.57% | 93.33% | 62.50% | 0.00% | 1.33% | 0.87% | -206.32% | 35.19% | 56.93% | 65.38% | -21.20% | 26.80% |
| Net Profit | 0.03 | 0.02 | 0.06 | -6.09 | 0.74 | 1.14 | 2.91 | 1.41 | 1.16 | 0.36 | 2.63 | 1.11 |
| EPS in Rs | 0.04 | 0.02 | 0.08 | -7.61 | 0.92 | 1.42 | 3.00 | 1.45 | 1.19 | 0.37 | 2.71 | 1.14 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 99 | 107 | 112 | 156 | 167 | 182 | 200 | 183 | 197 | 159 | 196 | 191 |
| Expenses | 94 | 101 | 105 | 138 | 148 | 159 | 194 | 182 | 186 | 152 | 176 | 171 |
| Operating Profit | 6 | 6 | 7 | 18 | 19 | 23 | 6 | 1 | 11 | 7 | 20 | 20 |
| OPM % | 6% | 6% | 6% | 11% | 11% | 13% | 3.2% | 0.5% | 6% | 4.5% | 10% | 10% |
| Other Income | -0 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 1 | 1 | 1 | 1 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 7 | 7 |
| Depreciation | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 6 | 6 | 6 | 7 |
| Profit before tax | 0 | 2 | 2 | 12 | 14 | 17 | 2 | 0 | 1 | -3 | 8 | 7 |
| Tax % | 18% | 24% | 28% | 39% | 23% | 21% | 34% | 311% | 77% | -60% | 31% | |
| Net Profit | 0 | 1 | 2 | 8 | 11 | 14 | 1 | -0 | 0 | -1 | 6 | 5 |
| EPS in Rs | 0.54 | 1.69 | 2.14 | 9.39 | 13.62 | 17.15 | 1.42 | -0.22 | 0.18 | -1.33 | 5.72 | 5.41 |
| Dividend Payout % | 0% | 0% | 0% | 11% | 7% | 9% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 7% | 2% | 2% | 5% | ||
| Compounded Profit Growth | 21% | -17% | 315% | -15% | ||
| Stock Price CAGR | 17% | -6% | 23% | -43% | ||
| Return on Equity | 10% | 2% | 2% | 8% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 3 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 |
| Reserves | -3 | 3 | 8 | 11 | 18 | 26 | 39 | 39 | 38 | 38 | 60 | 66 |
| Borrowings | 24 | 28 | 19 | 22 | 21 | 18 | 23 | 39 | 51 | 58 | 48 | 50 |
| Other Liabilities | 37 | 42 | 51 | 54 | 60 | 68 | 66 | 92 | 105 | 123 | 106 | 114 |
| Total Liabilities | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 223 | 240 |
| Fixed Assets | 24 | 27 | 33 | 34 | 38 | 39 | 44 | 49 | 54 | 52 | 50 | 46 |
| CWIP | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 | 12 | 21 | 23 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 42 | 47 | 52 | 60 | 68 | 80 | 92 | 121 | 136 | 153 | 150 | 171 |
| Total Assets | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 223 | 240 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 4 | 7 | 10 | 5 | 9 | 10 | 14 | 14 | 18 | 16 | -5 | 4 |
| Cash from Investing Activity | -3 | -7 | -8 | -4 | -5 | -6 | -12 | -17 | -16 | -13 | -5 | -2 |
| Cash from Financing Activity | -2 | -0 | -2 | -1 | -3 | -3 | -2 | 2 | -3 | -3 | 16 | -8 |
| Net Cash Flow | -0 | 0 | 0 | -0 | 1 | 0 | -0 | -1 | 0 | 0 | 6 | -6 |
| Free Cash Flow | 1 | 0 | 2 | 1 | 2 | 3 | 7 | -3 | 5 | 3 | -11 | 2 |
| CFO/OP | 52% | 119% | 162% | 64% | 50% | 51% | 59% | 214% | 1,981% | 149% | -76% | 21% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 100 | 117 | 105 | 124 | 95 | 97 | 102 | 125 | 152 | 185 | 202 | 216 |
| Inventory Days | 44 | 55 | 73 | 72 | 71 | 102 | 110 | 110 | 139 | 128 | 166 | 132 |
| Days Payable | 184 | 235 | 260 | 251 | 190 | 211 | 183 | 212 | 282 | 324 | 315 | 262 |
| Cash Conversion Cycle | -40 | -63 | -83 | -55 | -24 | -12 | 29 | 24 | 9 | -11 | 53 | 86 |
| Working Capital Days | -30 | -38 | -50 | -34 | -15 | 7 | 21 | 9 | -12 | -20 | 3 | 27 |
| ROCE % | 19% | 11% | 13% | 13% | 35% | 35% | 34% | 6% | 4% | 6% | 2% | 12% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 74.15% | 74.15% | 74.15% | 74.15% | 74.15% | 74.15% | 61.09% | 60.99% | 59.64% | 59.61% | 59.58% | 59.60% |
| DIIs | 0.03% | 0.03% | 0.03% | 0.03% | 0.05% | 0.05% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public | 25.82% | 25.82% | 25.83% | 25.83% | 25.81% | 25.80% | 38.90% | 38.99% | 40.35% | 40.36% | 40.40% | 40.38% |
| No. of Shareholders | 10,494 | 10,242 | 10,023 | 9,792 | 9,996 | 9,326 | 8,756 | 8,281 | 8,079 | 7,804 | 7,880 | 7,827 |
Fundamentals
Market Cap₹ 222 Cr.
Current Price₹ 223
Stock P/E42.2
Book Value₹ 77.7
ROCE12.0 %
ROE7.63 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)5%
Compounded Profit Growth (TTM)-15%
Standalone figures.
Valuation
Market capRs 213 Cr
Enterprise valueRs 263 Cr
P/E (TTM)40.58x
Price to book2.83x
Price to sales1.12x
EV / EBITDA12.62x
EV / EBIT18.42x
EV / sales1.38x
Price to cash flow51.18x
Earnings yield2.46%
P/E, 3-year average345.80x
P/B, 3-year average2.71x
P/E, 5-year average271.19x
P/B, 5-year average2.55x
Profitability
Operating margin (excl. other income)10.10%
Operating margin (incl. other income)10.74%
EBITDA margin10.91%
Pre-tax margin3.88%
Net profit margin2.76%
Net margin, latest quarter2.29%
ROE7.63%
ROCE11.99%
ROA2.40%
ROE, 3-year average1.90%
ROCE, 3-year average6.60%
ROA, 3-year average0.63%
ROE, 5-year average1.55%
ROCE, 5-year average5.95%
ROA, 5-year average0.50%
ROIC (approx.)7.88%
Tax rate31.06%
Other income / net worth1.66%
Growth
Sales growth (latest year)23.00%
Sales CAGR, 3 years2.33%
Sales CAGR, 5 years1.56%
Profit CAGR, 5 years-16.56%
Sales growth QoQ-0.66%
Profit growth QoQ-57.79%
Sales growth YoY (latest quarter)-10.00%
Profit growth YoY (latest quarter)-21.28%
Per share
EPS (TTM)Rs 5.42
EPS (latest year)Rs 5.72
EPS (latest quarter)Rs 1.14
EPS, 3-year averageRs 1.52
EPS, 5-year averageRs 1.15
Book value per shareRs 77.73
Sales per shareRs 196.46
Cash flow per shareRs 4.29
Free cash flow per shareRs 2.06
Efficiency
Asset turnover0.82x
Fixed asset turnover4.24x
Inventory turnover3.32x
Inventory days110 days
Debtor days216 days
Debtors turnover1.69x
Creditor days262 days
Cash conversion cycle86 days
Working capital days27 days
Leverage
Total debtRs 50 Cr
Cash and bankRs 1 Cr
Net debtRs 49 Cr
Debt to equity0.66x
Net debt / EBITDA2.37x
Interest coverage2.08x
Owners' fund to total sources31.47%
Debt to assets20.82%
Cash flow
Cash from Operating Activity (latest year)Rs 4 Cr
Cash from Investing Activity (latest year)Rs -2 Cr
Cash from Financing Activity (latest year)Rs -8 Cr
Net Cash Flow (latest year)Rs -6 Cr
Free cash flow (latest year)Rs 2 Cr
FCFE (approx.: FCF + change in debt)Rs 4 Cr
Cash from ops / profit, 5 years7.83x
Sales to cash flow47.04x
Statement figures
Net sales (TTM)Rs 191 Cr
Net sales (latest year)Rs 196 Cr
Sales (latest quarter)Rs 48 Cr
Operating profit excl. other income (latest year)Rs 20 Cr
Operating profit (latest quarter)Rs 4 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs 21 Cr
PBDT (TTM)Rs 14 Cr
Profit before tax (TTM)Rs 7 Cr
Tax (latest year)Rs 2 Cr
Net profit (TTM)Rs 5 Cr
Net profit (latest year)Rs 6 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 7 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 7 Cr
Cost of goods sold (latest year)Rs 149 Cr
Total expenditure (latest year)Rs 176 Cr
Total income (latest year)Rs 197 Cr
Share capitalRs 10 Cr
ReservesRs 66 Cr
Shareholders' fundsRs 75 Cr
Total assetsRs 240 Cr
Net blockRs 46 Cr
Capital work in progressRs 22 Cr
InvestmentsRs 0 Cr
ReceivablesRs 116 Cr
InventoryRs 45 Cr
Other liabilitiesRs 114 Cr
Shares outstanding (crore)0.97
Ownership
Promoter holding59.60% (-1.39 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 40.6 is at the 44th percentile of its own 7.2-year range
(median 49.8, low 11.4, high 120.0).
P/B 2.83 is at the 22th percentile (median 5.19).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 524790 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -8.2% | -2.8% | -5.5 pts |
| 1 month | -25.0% | -6.8% | -18.2 pts |
| 3 months | -13.4% | -7.6% | -5.8 pts |
| 3 years | +84.6% | +14.2% | +70.4 pts |
| 5 years | -26.8% | +27.9% | -54.6 pts |
Red flags
F-score 7 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹48 Cr -10.0% vs Jun 2025.
Net profit ₹1 Cr -21.3%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Everest Organics Ltd?
Everest Organics Ltd (524790) has a market capitalisation of Rs 222 Cr. at the 2026-10-01 close.
What is the P/E ratio of Everest Organics Ltd?
Everest Organics Ltd trades at a P/E of 42.2 on trailing twelve-month profit, at the 2026-10-01 close.
What were Everest Organics Ltd's latest quarterly results?
In the Jun 2026 quarter, Everest Organics Ltd sales was Rs 48 Cr (-10.0% vs Jun 2025) and net profit was Rs 1 Cr.